Literature DB >> 33915941

Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer.

Maša Brumec1, Monika Sobočan1,2,3, Iztok Takač1,3, Darja Arko1,3.   

Abstract

This review summarizes the recent findings of a vast array of studies conducted on androgen receptor-positive triple-negative breast cancer (AR-positive TNBC) to provide a better understanding of this specific breast cancer subgroup. AR expression is correlated with higher age, lower histological grade, lower proliferation index Ki-67, spiculated masses, and calcifications on mammography. Studies investigating the correlation between AR expression and lymph node metastasis are highly discordant. In addition, results regarding prognosis are highly contradictory. AR antagonists are a promising novel therapeutic approach in AR-positive TNBC. However, AR signaling pathways should be more investigated in order to understand the influence of AR expression on TNBC more thoroughly.

Entities:  

Keywords:  androgen antagonist; androgen receptor; triple-negative breast cancer

Year:  2021        PMID: 33915941     DOI: 10.3390/cancers13071642

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response.

Authors:  Kevin J Thompson; Roberto A Leon-Ferre; Jason P Sinnwell; David M Zahrieh; Vera J Suman; Filho Otto Metzger; Sarah Asad; Daniel G Stover; Lisa Carey; William M Sikov; James N Ingle; Minetta C Liu; Jodi M Carter; Eric W Klee; Richard M Weinshilboum; Judy C Boughey; Liewei Wang; Fergus J Couch; Matthew P Goetz; Krishna R Kalari
Journal:  NAR Cancer       Date:  2022-06-17

Review 2.  Translational Implications of Dysregulated Pathways and microRNA Regulation in Quadruple-Negative Breast Cancer.

Authors:  Amal Qattan; Taher Al-Tweigeri; Kausar Suleman
Journal:  Biomedicines       Date:  2022-02-02

3.  Chimeric Oncolytic Adenovirus Armed Chemokine Rantes for Treatment of Breast Cancer.

Authors:  Lin Ang; Jiang Li; Hui Dong; Chunhong Wang; Jin Huang; Mingcong Li; Min Zhao; Changqing Su; Qiang Wu
Journal:  Bioengineering (Basel)       Date:  2022-07-26

Review 4.  Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer.

Authors:  Nikita Jinna; Padmashree Rida; Max Smart; Mark LaBarge; Tijana Jovanovic-Talisman; Rama Natarajan; Victoria Seewaldt
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

5.  CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.

Authors:  Carla Gibbs; Jae Young So; Abdul Ahad; Aleksandra M Michalowski; Deok-Soo Son; Yang Li
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

Review 6.  Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic.

Authors:  Aglaia Skolariki; Jamie D'Costa; Martin Little; Simon Lord
Journal:  Explor Target Antitumor Ther       Date:  2022-04-24

7.  AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status.

Authors:  Mengping Long; Chong You; Qianqian Song; Lina X J Hu; Zhaorong Guo; Qian Yao; Wei Hou; Wei Sun; Baosheng Liang; Xiaohua Zhou; Yiqiang Liu; Taobo Hu
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.